Publication date: Jan 20, 2020
The current first-line treatment for Opioid Use Disorder (OUD) in Canada is buprenorphine/naloxone (Suboxone). The standard induction method of buprenorphine/naloxone requires patients to be abstinent from opioids and thereby experience withdrawal symptoms prior to induction, which can be a major barrier in starting treatment. Rapid micro-induction (micro-dosing) involves the administration of small, frequent does of buprenorphine/naloxone and removes the need for a period of withdrawal prior to the start of treatment. This study aims to compare the effectiveness and safety of rapid micro-induction versus standard induction of buprenorphine/naloxone in patients with OUD.
- Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal
- Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults
- Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
- A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
- Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report.
- Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion.